TianYu Bio-Technology Co EBITDA per Employee
The EBITDA per Employee of TianYu Bio-Technology Co (603717.SS) as of Oct 12, 2026 is -219,737.60 CNY. In the previous year, EBITDA per Employee was -173,333.23 CNY — a change of 26.77% (lower).
Get this data via API
Financial Data API
EBITDA per Employee
-219,737.60CNY
YoY
26.77%
Last updated:
The TianYu Bio-Technology Co EBITDA per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA per Employee | YoY |
|---|---|---|
| -219,737.60CNY | +26.77% | |
| -173,333.23CNY | -85.75% | |
| -1.22 MCNY | +95.47% | |
| -622,373.50CNY | +20.69% | |
| -515,666.57CNY | +49.69% | |
| -344,492.67CNY | -292.48% | |
| 178,979.19CNY | -49.54% | |
| 354,706.52CNY | +6.80% | |
| 332,131.50CNY | -11.21% | |
| 374,050.13CNY | +39.34% | |
| 268,448.12CNY | +7.56% | |
| 249,586.46CNY | — |
TianYu Bio-Technology Co Stock analysis
Frequently Asked Questions about TianYu Bio-Technology Co stock
EBITDA per Employee of TianYu Bio-Technology Co is -219,737.60 CNY in 2025.
EBITDA per Employee of TianYu Bio-Technology Co changed from -173,333.23 CNY to -219,737.60 CNY, representing a 26.77% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Employee TianYu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's TianYu Bio-Technology Co historically and in real time.
Workforce — TianYu Bio-Technology Co
All Key Metrics — TianYu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth